• Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

    News

    Gyros and DI Biotech Sign Distribution Agreement for the Korean Market

    Gyros® AB, a leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, a leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries. Gyrolab has rapidly become established as a preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organisations, in their drug development process and clinical trials, in both Europe and the USA. As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.

    “We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Walldén, CEO and President of Gyros. “It’s an organisation with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. S. E. Kim, CEO and President at DI Biotech comments: “We have already tested the market for Gyrolab in Korea, and the response was immediate and positive, which was very encouraging. The benefits that Gyrolab provides are recognised in all sectors of pharmaceutical development, as well as in government-funded institutes. Pharma, biotech and especially, the fast-growing CRO and CMO companies, all see possibilities, to not only ramp-up productivity, but also to boost their competitiveness. The financial standing of these industries was already strong, and coupled with the Korean government’s recent investment of the equivalent of 90 million EUR, to further propel the development of biotherapeutics within the ‘SMART project’, we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea.”


    Digital Edition

    ILM 50.2 March 2025

    March 2025

    Chromatography Articles - Effects of small deviations in flow rate on GPC/SEC results Mass Spectrometry & Spectroscopy Articles - Waiting for the present to catch up to the future: A bette...

    View all digital editions

    Events

    Bio-Europe Spring

    Mar 17 2025 Milan, Italy

    NGVS 2025

    Mar 18 2025 Beijing, China

    Laborama 2025

    Mar 20 2025 Brussels, Belgium

    Asia Labex

    Mar 20 2025 Chandigarh, India

    ACS National Meeting & Expo, Spring 2025

    Mar 23 2025 San Diego, CA, USA

    View all events

    Great Job...
    The latest issue will be with you shortly
    Sign up to Labmate for FREE.
    Register and get the eBulletin, a Monthly email packed with the latest Laboratory products, news and services. Join us and get the latest Laboratory information first.